RESUMO
Twelve derivatives of benzophenone (BP1-BP12) are widely used as UV-screens to protect industrial products from light induced damage. There is growing public concern about industrially produced chemicals that might interfere with hormonal signalling pathways, thus having potential adverse effects on human health. The derivative 2,2',4,4'-tetrahydroxybenzophenone (BP2) which is used in cosmetic products and in packaging materials, was previously shown to be an estrogenic endocrine active chemical (EAC). While the metabolisation of BP3 has been analyzed in vivo, according to our knowledge little is known about the pharmacokinetics of BP2. Therefore we performed a dose-response experiment with 5 dosages of BP2 which was applied per gavage to adult ovariectomised (ovx) rats for 5 days. Serum samples were analyzed via HPLC. Metabolites were further identified by Helix pomatia glucuronidase treatment and subsequent ion-trap-mass spectrometry. Additionally we analyzed the time dependent metabolisation and excretion of BP2 in a kinetic study. The parent compound BP2 is metabolised to glucuronide - and sulfate-conjugates. In the serum maximum levels of BP2, BP2-glucuronide and BP2-sulfate were observed already 30 min after BP2 application while highest concentrations of BP2 and its metabolites in urine were measured 120 min after treatment. It is suggested that this biotransformation occurs via a first-pass effect in the gut wall or the liver. Despite this rapid metabolisation and excretion, the amount of unconjugated BP2 was sufficient to induce a dose dependent estrogenic effect in the uterotrophic assay.
Assuntos
Benzofenonas , Estrogênios não Esteroides , Administração Oral , Animais , Benzofenonas/sangue , Benzofenonas/metabolismo , Benzofenonas/farmacocinética , Benzofenonas/urina , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Estrogênios não Esteroides/sangue , Estrogênios não Esteroides/metabolismo , Estrogênios não Esteroides/farmacocinética , Estrogênios não Esteroides/urina , Feminino , Espectrometria de Massas , Taxa de Depuração Metabólica , Tamanho do Órgão/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Útero/efeitos dos fármacosRESUMO
Endocrine disrupting chemicals (EDCs), either plant constituents or contaminants deriving from industrial products, may interfere with the thyroid hormone (TH) axis. Here, we examined whether selected EDCs inhibit the key reactions of TH biosynthesis catalyzed by thyroid peroxidase (TPO). We used a novel in vitro assay based on human recombinant TPO (hrTPO) stably transfected into the human follicular thyroid carcinoma cell line FTC-238. F21388 (synthetic flavonoid), bisphenol A (building block for polycarbonates), and the UV filter benzophenone 2 (BP2) inhibited hrTPO. BP2 is contained in numerous cosmetics of daily use and may be in regular contact with human skin. Half-maximal inhibition in the guaiacol assay occurred at 450 nmol/liter BP2, a concentration 20- and 200-fold lower than those required in case of the TPO-inhibiting antithyroid drugs methimazole and propylthiouracil, respectively. BP2 at 300 nmol/liter combined with the TPO substrate H(2)O(2) (10 mumol/liter) inactivated hrTPO; this was, however, prevented by micromolar amounts of iodide. BP2 did not inhibit iodide uptake into FRTL-5 cells. In BP2-treated rats (333 and 1000 mg/kg body weight), serum total T(4) was significantly decreased and serum thyrotropin was significantly increased. TPO activities in the thyroids of treated animals were unchanged, a finding also described for methimazole and propylthiouracil. Thus, EDCs, most potently BP2, may disturb TH homeostasis by inhibiting or inactivating TPO, effects that are even more pronounced in the absence of iodide. This new challenge for endocrine regulation must be considered in the context of a still prevailing iodide deficiency in many parts of the world.
Assuntos
Benzofenonas/toxicidade , Iodeto Peroxidase/antagonistas & inibidores , Proteínas de Ligação ao Ferro/antagonistas & inibidores , Hormônios Tireóideos/metabolismo , Animais , Autoantígenos , Extratos Celulares/análise , Células Cultivadas , Disruptores Endócrinos/toxicidade , Ativação Enzimática/efeitos dos fármacos , Feminino , Filtração , Humanos , Peróxido de Hidrogênio/farmacologia , Iodo/metabolismo , Iodo/farmacologia , Modelos Biológicos , Ratos , Ratos Sprague-Dawley , Proteínas Recombinantes/antagonistas & inibidores , Raios UltravioletaRESUMO
Octyl-methoxycinnamate (OMC) is one of the most frequently used UV-filters in sunscreens to protect the skin against the noxious influence of UV radiation. Recently, OMC was suspected to act as an "endocrine active chemical" (EAC) with estrogenic actions. While EACs have been investigated thoroughly for interference with reproductive function in mammalians, surprisingly little efforts have been made to investigate an interference of EACs with the hypothalamo-pituitary-thyroid (HPT) axis despite the expression of estrogen receptors in all parts of this axis. Therefore, we conducted an in vivo study with ovariectomised rats treated for 5 days with different doses of OMC or 17beta-estradiol (E2) as a control. Determined parameters comprised serum levels of TSH, T4 and T3, hypothalamic TRH mRNA expression, protein-expression of the sodium-iodide-symporter (NIS) and the TSH receptor and the activities of thyroid peroxidase (TPO) in the thyroid and the T3-responsive hepatic type I 5'deiodinase (Dio1) in the liver. While E2 did not affect TSH-, T4- or T3-levels, OMC caused a dose-dependent decrease of serum concentrations of all of these hormones. TRH expression remained unaffected, while in the thyroid, expression of the TSH receptor but not of NIS was stimulated by OMC. TPO activity was unaltered but Dio1 activity was reduced by OMC. Thus, our results demonstrate a non-estrogenic interference of OMC within the rodent HPT axis with inadequate feedback response to impaired thyroid hormone status, indicated by decreased serum thyroid hormone and hepatic Dio1 levels.
Assuntos
Cinamatos/toxicidade , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Protetores Solares/toxicidade , Animais , Western Blotting , Cinamatos/administração & dosagem , Cinamatos/química , Relação Dose-Resposta a Droga , Feminino , Sistema Hipotálamo-Hipofisário/fisiologia , Iodeto Peroxidase/metabolismo , Iodo/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Ovariectomia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Radioimunoensaio , Ratos , Ratos Sprague-Dawley , Receptores da Tireotropina/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Protetores Solares/administração & dosagem , Protetores Solares/química , Simportadores/metabolismo , Tireoglobulina/metabolismo , Tireotropina/metabolismo , Hormônio Liberador de Tireotropina/genética , Hormônio Liberador de Tireotropina/metabolismo , Tiroxina/metabolismo , Fatores de Tempo , Tri-Iodotironina/metabolismoRESUMO
Sun protection products contain a variety of UV-filters, among others, octyl-methoxycinnamate (OMC). Recently, an uterotrophic effect in immature rats has been reported, indicating that OMC might have estrogenic properties and thus is an endocrine active chemical (EAC). However, determination of an estrogenic activity in the uterus only is a restricted approach with the potential risk of missing undesirable actions in other organs regulated by estrogens. A pharmacodynamic experiment with 5 dosages of OMC in adult ovariectomized (ovx) rats was carried out to quantify the multi-organic estrogenic properties of OMC. As control compound, estradiol-valerate (E2) was included. Animals were treated per gavage for 5 days. The expression levels of markers of estrogenic action in several organs were measured by RT-PCR. Effects on metabolic parameters were assessed by determination of the serum concentrations of leptin, cholesterol, high and low density lipoproteins (HDL and LDL), glucose and triglycerides. Observed changes upon OMC treatment were analyzed using the NO(A)EL and the benchmark dose approach. From the obtained pharmacodynamic data of the most sensitive parameter (truncated estrogen receptor protein 1 gene expression in the pituitary) we obtained threshold values that are exceeded by the recommended use of OMC containing formulations for skin protection in humans, therefore we propose to reduce the use of OMC in cosmetic products. In addition to estrogenic actions of OMC, non-estrogenic effects have been found for this chemical supporting the need of a multi-organic risk assessment of putative EACs.
Assuntos
Cinamatos/farmacologia , Estrogênios não Esteroides/farmacologia , Fígado/efeitos dos fármacos , Hipófise/efeitos dos fármacos , Protetores Solares/farmacologia , Útero/efeitos dos fármacos , Animais , Peso Corporal/efeitos dos fármacos , Complemento C3/biossíntese , Relação Dose-Resposta a Droga , Receptor beta de Estrogênio/biossíntese , Feminino , Lipídeos/sangue , Fígado/metabolismo , Tamanho do Órgão/efeitos dos fármacos , Hipófise/metabolismo , Ratos , Ratos Sprague-Dawley , Receptor IGF Tipo 1/biossíntese , Receptores de Estrogênio/biossíntese , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Medição de Risco , Útero/metabolismoRESUMO
The estrogen receptors (ERs) are members of a super family of ligand-activated transcription factors mediating estrogenic responses. A close functional kinship was found for the structurally related estrogen receptor-related receptor1 (ERR1), a constitutively active transcription factor. The aryl hydrocarbon receptor (AhR) mediates the toxic and estrogenic effects of a wide variety of environmental contaminants and industrial pollutants. Both the ERR1 and the AhR are known to modulate the ER's signalling pathways in multiple ways. Organic chemicals with a certain structural relationship to steroid hormones often induce a tissue- or cell-specific variety of responses distinct from estrogenic responses and this may involve ERR1 and AhR. The UV-screens benzophenone-2 and benzophenone-3 (BP2, BP3), structurally related to known steroid receptor ligands, are used in cosmetics and plastics to improve product stability and durability. Both BP2 and BP3 were shown to exert uterotrophic effects and BP2 was shown to bind to the estrogen receptors. Whether such effects are also exerted in other organs is unknown. Therefore, an approach to a multi-organic risk assessment for these substances was made by measuring the gene-expression of the four mentioned receptors in the pituitary, the uterus and the thyroid after a five-day treatment in comparison to estradiol. Though BP2 seems to exert an estrogen-like effect while BP3 does not, there are regulatory effects on receptor expression for both substances that indicate a kind of endocrine disruption that is not assessed by "classical" estrogenic markers.
Assuntos
Benzofenonas/toxicidade , Estradiol/toxicidade , Receptor alfa de Estrogênio/genética , Receptor beta de Estrogênio/genética , Receptores de Hidrocarboneto Arílico/genética , Receptores Citoplasmáticos e Nucleares/genética , Receptores de Estrogênio/genética , Animais , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Ovariectomia , RNA Mensageiro/análise , Ratos , Ratos Sprague-Dawley , Receptor ERRalfa Relacionado ao EstrogênioRESUMO
The tetrahydroxylated biphenyl-ketone 2,2',4,4'-tetrahydroxybenzophenone (BP2), one of twelve benzophenone-derived UV-filters, is used in cosmetic products and in packaging materials to protect these products from light induced damage. Recently published studies showed that BP2 exerts estrogenic activity; thus, it is an endocrine active chemical. We present data from a pharmacodynamic dose-response experiment with five dosages of BP2 applied per gavage to adult ovariectomized (ovx) rats for 5 days. Estradiol-valerate (E2) served as a control compound. The uterotrophic assay, proposed by the OECD, was modified to have a broader view on endocrine activity outside the urogenital tract to prevent that undesirable actions in other organs regulated by estrogens are missed. The gene expression levels of marker genes of estrogenic action were measured by semi-quantitative RT-PCR. Metabolic parameters were assessed by determination of the serum concentrations of leptin, cholesterol, high- and low-density lipoproteins, and triglycerides in the serum. Administration of BP2 at dosages of 10-1,000 mg/kg bodyweight led to changes of these parameters comparable to the changes in the E2 group with 0.6 mg/kg bodyweight. For the observed estrogenic activities of BP2, the "no observed adverse effect levels" were determined. Additionally, the data were further analyzed using the benchmark approach. If BP2 is transcutaneously absorbed in the human, the obtained threshold values would suggest refraining from the further use of BP2 as UV-filter in cosmetic products although additional toxicological studies should be conducted to clarify possible adverse effects.